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Background: Differentiated thyroid cancer (DTC) occurs in relatively young patients and is 
associated with a good prognosis and long survival. The management of this disease involves 
thyroidectomy, radioiodine therapy, and long-term thyroid-stimulating hormone suppression 
therapy (THST). The long-term effects of the treatment and the interaction between subclinical 
hyperthyroidism and long-term hypoparathyroidism are poorly understood. This review sought 
to examine the available evidence.
Methods: A PubMed search was carried out using the search terms “Thyroid Neoplasms” AND 
(“Thyroxine” OR “Hypocalcemia” OR “Thyrotropin”). Original English language articles published 
in the last 30 years studying the morbidity from thyroid-stimulating hormone (TSH) suppression 
and hypoparathyroidism following a surgery for DTC were retrieved and reviewed by 2 authors.
Results: Of the 3,000 results, 66 papers including 4,517 patients were selected for the present 
study. Studies reported on a range of skeletal (included in 34 studies, 1,647 patients), cardiovas-
cular (17 studies, 957 patients), psychological (10 studies, 663 patients), and other outcomes (10 
studies, 1,348 patients). Nine of 26 studies on patients who underwent THST showed a reduction 
in bone density, and 13 of 23 studies showed an increase in bone turnover markers. Skeletal 
effects were more marked in postmenopausal women. There was no evidence of increased 
fracture risk, and only little data were available on hypoparathyroidism. Four of five studies 
showed an increased left ventricular mass index on echocardiography, and one study showed a 
higher prevalence of atrial fibrillation (AF). There was little difference in basic physiological 
parameters and limited literature regarding symptoms or significant events. Six studies showed 
associations between long-term TSH suppression and impaired quality of life. Impaired glucose 
metabolism and prothrombotic states were also found in DTC patients.
Conclusion: There is limited literature regarding long-term DTC treatment-related morbidity, 
particularly regarding the effects of long-term hypocalcemia. Most studies have focused on 
surrogate markers and not on clinical outcomes. A large prospective study on defined clinical 
outcomes would help characterize the morbidity of treatment and stimulate research on tailor-
ing treatment strategies.
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Introduction
Differentiated thyroid cancer (DTC) is the most common form of thyroid cancer. It 
includes papillary (80%) and follicular (15%) subtypes, as well as a small proportion 
of mixed tumors.
Women are more commonly affected by DTC than men with a ratio of ~3:1. Age 
distribution is binomial with peaks between 35 and 39 years and >70 years. Almost 
half of the cases are diagnosed in patients aged <50 years. Despite the relatively young 
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average age, patients with DTC generally have a good prog-
nosis of ~90% 5-year survival rate.1 
In the last few decades, the incidence of thyroid cancer 
has increased 2.4-fold, higher than that of any other cancer 
among the US population. Greater diagnostic yield may play 
a role, but the incidence of cancers with a more aggressive 
subtype is also increasing.2 The standard treatments for DTC 
in the UK include total thyroidectomy (TT) for most patients 
with a tumor >1 cm in size, radioactive iodine (RAI) ablation 
therapy for the majority of patients, and long-term thyroid-
stimulating hormone suppression therapy (THST). Practice 
across the world broadly includes the same strategy.3
The THST, by definition, leads to a state of at least 
subclinical hyperthyroidism, typically resulting in a low 
thyroid-stimulating hormone (TSH), high or high–normal 
thyroxine (T4) or free T4 (FT4), and a normal triiodothy-
ronine (T3) or free T3.3 This is in contrast with the typical 
profile in endogenous hyperthyroidism. Both endogenous 
hyperthyroidism and subclinical hyperthyroidism have long 
been linked to long-term adverse effects, particularly on the 
skeletal system. Thyroid hormone induces bone resorption 
via thyroid receptors TRα4 or TRβ5 on osteoclasts and osteo-
blasts. TSH may also have direct effects on bone metabolism.6 
In addition, thyroid hormone also has well-characterized 
cardiovascular effects including increasing systolic blood 
pressure (BP), cardiac contractility, heart rate (HR), and 
tachyarrhythmias.7 Chronic endogenous hyperthyroidism can 
also lead to echocardiographic evidence of both systolic and 
diastolic dysfunctions in a significant proportion of patients.8 
In addition, thyroidectomy for DTC may be accompanied 
by unintentional parathyroid damage or removal, resulting in 
postsurgical hypoparathyroidism. The latter may be transient, 
typically resolving shortly after surgery, or permanent, with 
potential long-term consequences. Hypoparathyroidism is 
known to reduce bone turnover and to increase bone mineral 
density (BMD)9 and can lead to metastatic calcification.10 
This may be exacerbated by the additional calcium supple-
mentation that is often required by these patients.11 Some 
studies have examined the incidence of postthyroidectomy 
hypocalcemia,12 but the long-term adverse effects of this 
treatment have not been well characterized in the DTC popu-
lation. A recent study of patients with hypoparathyroidism 
following thyroidectomy for various indications demon-
strated an increased tendency for infective and psychiatric 
illnesses and a reduced risk of fractures.13 
There have been numerous small studies on DTC-related 
skeletal treatment-related morbidity (TRM), and these studies 
have been reviewed previously.14,15 However, more recently, a 
significant number of studies have been published, and there 
have been changes in surgical and endocrine practice, the 
assessment of BMD, biochemical measurement, and thyrox-
ine dosing. There is also a lack of comprehensive review on 
the nonskeletal effects, and therefore, the present systematic 
review aimed to include up-to-date evidence of the long-term 
effects of DTC treatment on skeletal, cardiovascular, and 
other aspects of health.
Review
On June 28, 2014, the National Center for Biotechnology 
Information PubMed Central database was searched for 
articles using the Medical Subheading terms “Thyroid Neo-
plasms” AND (“Thyroxine” OR “Hypocalcemia” OR “Thy-
rotropin”). This search yielded 2,866 results, the abstracts 
of which were reviewed where applicable. All the original 
articles reporting on incidence, prevalence, and/or severity 
of morbidity relating to either postoperative hypocalcemia 
or TSH suppression in human patients who underwent 
treatment for DTC were considered for inclusion. Studies 
were excluded if they were published before 30 years; were 
not original studies (such as reviews, editorials, letters, and 
guidelines); did not include in vivo work on human subjects; 
were conducted on other populations or with no separate 
analyses of patients with DTC; involved nonstandard inter-
ventions; had outcomes not relevant to the research question 
(eg, short-term complications); were single-case reports; and 
were studies without a control group matched in some way 
with the population of interest. If the title and/or abstract of 
any study was unclear as to whether it should be included, 
the full text of that particular study was obtained for review 
(Figure 1). Then, the full texts of all the papers deemed 
suitable for inclusion were obtained, and the key data from 
these studies were recorded on a data-collection pro forma. 
Then, the data were transferred to an electronic database. 
The manuscripts were reviewed independently by 2 authors 
in order to validate the collected information. In total, 64 
papers were included. The search was updated during the 
preparation of the manuscript on November 25, 2015 using 
the same search terms. A further 134 new abstracts were 
reviewed, from which two suitable papers were included.16,17
Characteristics of the papers included
In total, 66 original papers were included in the final analysis. 
These were mainly European studies, and a significant num-
ber of studies were published in the last decade (Figure 2). 
Thirty-four papers included skeletal outcomes, whereas 17, 
10 and 10 papers included cardiovascular, psychological and 
other aspects, respectively. The present study reviewed for the 
presence of significant findings, those with a p-value <0.05.
Pragmatic and Observational Research 2017:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
59
Treatment-related morbidity in thyroid cancer
Summary
Skeletal effects
Thirty-four papers included data on skeletal outcomes, with a 
total of 1,647 patients. Table S1 summarizes the characteristics 
of these studies.18–24 The majority of them were observational 
cross-sectional studies although there was a randomized 
controlled trial.25 Some studies were primarily carried out 
to examine the effects of thyroid hormone withdrawal or 
the administration of recombinant TSH but also provided 
relevant data for inclusion in the present review. Two stud-
ies grouped all women together,25,26 22 studies reported on a 
separate premenopausal group, and 27 studies reported on a 
separate postmenopausal group. Twelve studies reported on 
a male cohort. The majority of study populations had under-
gone total or near TT followed by RAI and THST. In all but 
6 studies,25,27–31 the control groups were comprised of healthy 
euthyroid-matched individuals or local reference popula-
tions. In 2 studies,28,30 the control group suffered from benign 
thyroid disease. Women with known osteoporosis suffering 
with DTC were compared with those with osteoporosis but 
no DTC in one case,29 and women with DTC and THST were 
compared with those with DTC but no THST (with the aim 
Figure 1 Flowchart of the systematic review process used to obtain relevant research articles.
Excluded (total 2,767)
Study on patients  >30 years old 645
Non-English Language 36
Reviews 326
Animal studies 129
In vitro studies 207
Editorials, Commentaries and
Letters 110
Guidelines 13
Case reports 256
Wrong population 482
Nonstandard intervention 25
Outcome not of interest 521
No control group 17
Unclear from abstract review
39
Full-text review
Included
4
Excluded (total 35)
Wrong population 5
Nonstandard intervention 1
Outcome not of interest 24
No control group 5
PubMed search
June 28, 2014
2,866 results
Abstract review
Included
60
Included
64
Total to be included
66 Studies
Included
2
Excluded (total 132)
Search updated November 25, 2015
134 new abstracts
Non-English Language 10
Reviews 17
Animal studies 6
In vitro studies 10
Editorials, Commentaries and
Letters 4
Guidelines 1
Case reports 11
Wrong population 28
Nonstandard intervention 2
Outcome not of interest 41
No control group 2
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of euthyroidism) in two cases.25,27 One study31 stratified DTC 
patients by parathyroid hormone levels (13 of 33 patients had 
hypoparathyroidism) and found increased BMD, reduced rate 
of BMD loss, and reduced bone turnover markers in hypopara-
thyroid versus normoparathyroid patients. Thirty-one studies 
either excluded patients with hypoparathyroidism or found no 
evidence of it in the studied population. In 26 studies, BMD 
was determined, and in 22 studies, bone turnover markers 
were measured. Other outcomes included the response of 
BMD to alendronate29 and the risk of low-impact fractures.32 
BMD
Of the 26 studies that assessed the effect of THST in DTC 
patients on BMD, 9 showed some evidence of reduced BMD 
in patients on THST compared with controls.17,29,30,33–38 Table 
1 summarizes the results of studies that compared BMD at 
common sites in premenopausal, postmenopausal, or male 
patients with DTC on THST against healthy controls.
Overall, 2 of 17 studies34,38 that included a premenopausal 
female cohort and 5 of 21 studies17,33–35,38 that included a post-
menopausal female cohort demonstrated reduced BMD com-
pared with healthy controls. Of the studies that included a control 
group patients with benign thyroid disease either on THST30 or 
in the euthyroid state,30 there was an evidence of reduced BMD 
(in the mid-radius) in the former, but not in the latter. Ten stud-
ies including a total of 136 male patients showed no significant 
differences in BMD when compared with control group.26,32,39–46
The one randomized controlled trial of THST versus 
“replacement only,” carried out in Japan and included 144 
female DTC patients, showed reduced BMD at 1 year in 
patients in their above 50s and at 5 years in all age-groups on 
THST.25 One paper that stratified patients by TSH found no 
significant differences in BMD between those with euthyroid 
and subclinical hyperthyroid status.27 Another paper that 
studied the effectiveness of alendronate in improving BMD 
found that BMD was reduced in DTC patients on THST 
compared with controls.29
Bone turnover markers
Twenty-three studies included the measurement of bone 
turnover markers, and 13 (57%) studies showed an increase 
in bone turnover markers compared with controls, with no 
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Figure 2 Characteristics of papers reporting on DTC treatment–related morbidity included in this systematic review, classified by (A) country of origin, (B) outcomes 
studied, and (C) year of publication.
Abbreviation: DTC, differentiated thyroid cancer.
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difference in the remainder (43%); in those studies that 
showed a difference, there was a range of different findings 
as summarized in Table 2.
Other musculoskeletal outcomes
Only one study assessed the risk of low-impact fracture as 
an outcome and found no difference between the patients 
and controls.32 Schneider et al studied the muscle strength 
using grip testing and showed no difference between male 
or premenopausal female patients and healthy controls.45
Cardiovascular morbidity
There were 14 studies related to cardiovascular morbidity and 
one study related to mortality. The latter study demonstrated 
a significant increase in both cardiovascular (p<0.001) and 
all-cause (p<0.001) mortality in a cohort of 524 patients with 
thyroid cancer compared with 1,572 controls over a median 
follow-up period of 8.5 years.47 
The studies on cardiovascular morbidity included a 
range of physiological and pathological parameters (Table 
3). The subjects included in these studies were patients 
treated for DTC with THST, and the controls were healthy, 
age- and sex-matched euthyroid individuals unless oth-
erwise stated. Only one study included a measure of 
cardiovascular symptoms, and these symptoms were more 
prevalent in DTC patients than in a healthy control group.48 
Table S2 summarizes the characteristics and key findings 
of the studies.
Table 1 Studies that included the measurement of bone mineral density in DTC patients on THST and healthy controls across various 
subgroups and sites
Site Group Number of studies Total number 
of patients
Number of studies showing 
significant reduction*
Number of studies 
showing no difference*
Lumbar spine Premenopausal women 14 358 0 14
Postmenopausal women 13 366 3 10
Men 6 101 0 6
Neck of femur Premenopausal women 14 372 1 13
Postmenopausal women 14 346 3 11
Men 7 120 0 7
Ward’s triangle Premenopausal women 6 143 0 6
Postmenopausal women 7 173 1 6
Men 2 23 0 2
Trochanteric Premenopausal women 6 132 0 6
Postmenopausal women 7 147 1 6
Men 3 42 0 3
Notes: *In DTC groups compared with controls. p<0.05 was considered significant. No studies showed a significant increase in BMD in patients versus controls.
Abbreviations: BMD, bone mineral density; DTC, differentiated thyroid cancer; THST, thyroid-stimulating hormone suppression therapy.
Table 2 Summary of the findings from studies of markers of bone turnover in patients with DTC on long-term THST
Marker Premenopausal women Postmenopausal women Men
Alkaline phosphatase No evidence of significant difference Increased29,33,35,38 Increased43
Osteocalcin Increased38,46 Increased18,29,38 No evidence of significant difference
Hydroxyproline Increased33,46 Increased33,46 No evidence of significant difference
Type 1 collagen crosslinks Increased19,37,45,46 Increased19,29,37,44,45 Increased19–21,44
Osteoprotegerin Increased37 Increased,37,43 reduced28 Increased,20 reduced21
RANK-ligand Increased,28 reduced44 Reduced44 Reduced20,21,44
Abbreviations: DTC, differentiated thyroid cancer; THST, thyroid-stimulating hormone suppression therapy; RANK, receptor activator of nuclear factor kappa-B.
Table 3 Summary of the findings from studies of long-term cardiovascular outcomes in patients with DTC
Variable Number of studies n(DTC) Summary
Heart rate 9 170 Increased resting heart rate in 1 of 9 studies
Blood pressure 10 223 Increased systolic and mean blood pressure in 1 of 10 studies
Prevalence of AF 1 136 Increased
LV mass 6 116 Increased in 4 of 6 studies
LV ejection fraction (systolic function) 5 90 No evidence of difference
Diastolic function 4 74 Evidence of higher markers of diastolic dysfunction in 1 of 4 studies
Cardiovascular mortality 1 524 Increased compared with controls
Response to exercise 1 29 Reduced VO2max and peak heart rate
Abbreviations: AF, atrial fibrillation; DTC, differentiated thyroid cancer; LV, left ventricular; VO2max, maximal oxygen consumption.
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HR
Nine studies reported on resting HR in a total of 170 DTC 
patients on THST and compared them against healthy con-
trols. All but one study found no significant differences in 
resting HR between the patients and controls.48–55 One study 
showed an increase in HR compared with controls.56 Another 
study demonstrated no significant differences in minimum 
and maximum HRs, but a significant reduction in 1-minute 
HR variability in DTC patients.52 One study showed no sig-
nificant differences between patients and controls in supine 
and standing HRs, but some evidence of reduced autonomic 
activity.51,57
BP
Ten studies studied BP in a total of 223 DTC patients on 
THST and 275 healthy controls. One study found a sig-
nificantly higher mean and systolic BP in cancer patients,57 
whereas others found no significant difference. No study 
found a significant difference in diastolic BP between both 
the groups.49–51,53–59 There were no significant differences 
in systemic vascular resistance in 2 studies.50,56 One study 
demonstrated lower small and large artery elasticity in DTC 
patients on THST,56 whereas another study assessed brachial 
artery flow and glyceryl trinitrate-mediated dilatation and 
found no difference.59
Arrhythmia
The prevalence of AF in 136 DTC patients on THST over an 
11-year period was compared with that of a population refer-
ence group and found to be elevated.60 Gen et al showed both 
increased maximum P-wave duration and P-wave dispersion 
in DTC patients compared with controls.61 However, there 
was no significant difference in the frequency of atrial or 
ventricular premature beats on Holter monitoring in another 
study.48 
Echocardiography
Echocardiographic parameters were measured in 6 studies. 
These studies included a total of 116 patients with DTC on 
THST and 130 healthy matched controls. There was a wide 
range of data on structural measurements. Five studies48,50,54–56 
measured interventricular septal thickness. Two papers 
demonstrated this to be significantly increased in patients 
with DTC compared with controls,55,56 but no significant 
difference was found in the remainder.48,50,54 Left ventricular 
(LV) posterior wall thickness was found to be significantly 
increased in patients with DTC versus controls,55 but relative 
LV wall thickness was not different.53 In 4 of the 6 studies, 
LV mass index was shown to be significantly increased in 
patients with DTC compared with controls,48,54–56 but no dif-
ference was found in 2 studies.50,53 No paper demonstrated 
differences in LV end systolic diameter, LV end diastolic 
diameter, fractional shortening, LV ejection fraction, stroke 
volume, or cardiac output. Abdulrahman et al used speckle 
tracking echocardiography to assess LV strain in 14 DTC 
patients on THST and found a significant reduction in both 
circumferential and longitudinal but not radial strain, when 
compared with 24 controls.54
In addition to systolic function, 4 papers studied diastolic 
function.48,50,53,55 The early LV filling velocity was measured 
by using pulse wave Doppler (E) imaging in all and found to 
be significantly reduced in DTC patients in two studies.53,55 
The late ventricular filling velocity (A) was not significantly 
different in controls, but despite this, there was no demonstra-
ble significant difference in the E/A ratio. The tissue Doppler 
imaging was able to demonstrate a significant reduction in 
E′/A′ in 14 DTC patients on THST for an average of 1 year, 
indicating a tendency toward diastolic dysfunction compared 
with controls.55 No differences in left atrial diameter were 
detected. In contrast, Taillard et al measured the isovolumetric 
relaxation and LV deceleration times and found no difference 
in the patients compared with controls.53
Response to exercise
Vigario et al assessed response to cardiopulmonary exercise 
in 29 DTC patients who had been on THST for an aver-
age of 6 years and found a significant reduction in VO
2max
, 
workload, exercise intensity, peak HR, and HR variability in 
comparison with a group of 35 healthy matched controls. BP 
response to exercise and perception of breathlessness were 
not significantly different between the 2 groups.49
Cognitive and psychological functions
Jaracz et al assessed cognitive function in 31 patients on 
THST for DTC.62 They found that DTC patients made sig-
nificantly more preservative and nonpreservative errors and 
completed fewer categories in the Wisconsin Card Sorting 
Test compared with age- and sex-matched healthy controls. 
In addition, these patients generated fewer words in the Oral 
Word Association Test and took longer time to complete Trail 
Making Tests. This suggested some impairment in executive 
functions and visuospatial working memory. No differences 
were found between the groups in scores of the Stroop Test 
and digital span, which also assesses executive functions, 
working memory, and attention.
In addition, Botella-Carretero et al also found some 
cognitive impairment in DTC patients on THST by using the 
WAIS digit span test. However, there was no difference in 
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the other three cognitive tests used (ie, WAIS Digit Symbol, 
Davis Visual Scanning, and Cognitive Visual Analogical 
Mental Scales compared with controls).63
Moon et al did not find any differences in cognitive 
functions between 50 elderly DTC patients undergoing long-
term TSH suppression compared with 90 matched healthy 
controls. Interestingly, in patients with DTC, higher levels of 
FT4 were associated with better scores in Mini Mental State 
Examination and Trail Making Test A.16
Quality of life
Botella-Carretero et al found that 18 DTC patients scored 
significantly worse on the Nottingham Health Profile and 
on general health, mental health, and social functions of the 
Short Form (SF)-36 Health Survey compared with healthy 
controls.63 
Crevenna et al assessed the quality of life (using German 
version of SF-36) in 150 patients with nonmetastatic thyroid 
cancer on the long-term TSH suppression. Overall, patients 
scored worst in domains that assessed emotions, mood and 
energy levels, and limitation of activities due to emotional 
state (vitality and role emotions). In a subgroup analysis of 
patients assessed within 1 year of diagnosis of thyroid cancer, 
impairment was observed in more domains (mental health, 
role – emotional, role – physical, social functioning, and 
vitality) compared with reference values. Conversely, DTC 
patients scored better in items that evaluated general health 
and bodily pain.64
Eustatia-Rutten et al found that 24 patients with DTC 
undergoing long-term TSH suppression had significantly 
more somatic symptoms compared with reference values 
(Somatic Disorder Questionnaire [SDQ] total). However, 
they scored better on symptoms of low mood (depressive 
symptoms on Hospital Anxiety Depressive Score [HADS]). 
No significant difference was found in other quality of life 
parameters between the values of patients and reference 
values (SF-36, Multidimensional Fatigue Index-20 [MFI-20], 
Symptom Rating Scale, and HADS).65 
Hoftijzer et al assessed the quality of life in 153 patients 
treated with TSH suppression followed by TT and radioio-
dine ablation for DTC.66 Using 4 validated questionnaires 
(ie, SF-36, MFI-20, HADS, and SDQ), patients were shown 
to have a significantly worse quality of life in at least 11 of 
16 categories compared with controls. No association was 
found between serum TSH levels and quality of life. However, 
longer duration of cure from thyroid cancer was associated 
with improved quality of life.
Tagay et al evaluated the quality of life in 100 patients 
with DTC following TT, RAI, and TSH suppression. DTC 
patients scored significantly worse in all items of the SF-36 
except for 1 item (bodily pain), when compared to Ger-
man reference population.67 The total score of the mental 
components of the SF-36 was also significantly lower in 
DTC patients; however, there was no difference in physical 
component scores. In addition, the prevalence of anxiety and 
depressive symptoms (assessed by HADS, BDI, and Profile 
of Mood States) was within normal limits.
Vigario Pdos et al assessed fatigue perception, physical 
activity, and body composition in 36 patients with DTC 
following chronic THST.68 DTC patients had significantly 
smaller muscle mass and mid-thigh girth compared with 
healthy controls with sedentary lifestyles. There were no 
significant differences in body weight, body mass index, body 
fat, lean muscle mass, bone mass, residual mass, abdominal 
girth, and calf girth between the patients and controls. In 
addition, DTC patients reported significantly greater fatigue 
assessed on the Chalder fatigue scale, which assesses physi-
cal fatigue, tiredness, weakness, and muscle pain. The same 
groups were able to show that an exercise program improved 
their quality of life outcomes.69
Glucose metabolism
In a randomized controlled trial, Heemstra et al analyzed the 
effects of long-term TSH suppression on glucose and lipid 
metabolism in patients with DTC.70 At 6-month follow-up, 
there was no difference in glucose tolerance, insulin sensitiv-
ity, lipid profile, and glucoregulatory hormone levels between 
TSH-suppressed (n=13) and euthyroid (n=12) patients. 
Hsieh et al examined the effect of hyperthyroidism on 
leptin concentration and body composition in patients with 
DTC.71 No significant difference was found in leptin con-
centration between euthyroid DTC patients and controls. 
However, no comparison was made between TSH-suppressed 
patients and controls. 
Rezzonico et al assessed the association between insulin 
resistance and subclinical hyperthyroidism in 125 patients,72 
20 of whom had DTC. In subclinical hyperthyroidism, insu-
lin and glucose were significantly higher at baseline and 2 
hours after a standard meal. Insulin resistance (measured 
by homeostatic model assessment, the quantitative insulin 
sensitivity check index, and Avignon’s index amended by 
Aloulou) was significantly higher in patients with subclini-
cal hyperthyroidism compared with controls. However, there 
was no significant difference in the secretion of insulin by 
pancreatic β cells between the patients and controls.
Mittal et al evaluated increases in cardiovascular risk 
in 50 patients with DTC. Serum glucose was significantly 
lower and insulin level was higher in DTC patients compared 
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with controls, although treatment details were not fully 
described.58 However, there was no significant difference 
in glycated hemoglobin (HbA1c) levels. Total cholesterol, 
high-density lipoprotein, and low-density lipoprotein were 
significantly lower in DTC patients compared with controls, 
but no difference was found in triglycerides and very-low-
density lipoprotein levels.
Table 4 summarizes the key findings of studies on cogni-
tive function, quality of life, and glucose tolerance.
Coagulation
Horne et al examined the effects of chronic THST on coagula-
tion in 14 patients following TT for DTC.73 Patients on THST 
had significantly higher levels of a range of coagulation-
related substances including prothrombin fragments 1 and 
2, fibrinogen, factor VIII, antithrombin, tissue plasminogen 
activator (tPA), plasminogen activator inhibitor I (PAI-1), 
and PAI-1/tPA. Conversely, plasmin–antiplasmin complexes 
were lower. Other factors studied (plasminogen, factor II, and 
d-dimer) did not significantly change. Overall, the findings 
suggested a prothrombotic state during TSH suppression.
Immunology
In a study of 22 patients with DTC, Botella-Carretero et al 
found that TSH suppression significantly increased serum 
interleukin (IL)-18, soluble IL-2 receptor, and proportion 
of natural killer cells compared with euthyroid controls.74 
The implications of these changes in patients with DTC are 
unclear. 
Conclusion
A range of studies examining skeletal, cardiovascular, and a 
small number of other outcomes were studied in this review. 
There is some evidence that BMD is reduced, particularly in 
postmenopausal women treated for DTC compared with the 
general population, and there is also some evidence of sig-
nificant differences in various echocardiographic parameters, 
notably markers of diastolic dysfunction, and of increased 
tendency for atrial arrhythmia.
It is important to clarify TRM in this population as a sig-
nificant proportion of the adverse effects of DTC treatment 
are potentially preventable and/or reversible. For example, 
there is some evidence of the reversibility of diastolic dys-
function when THST is discontinued,75 and beta blockade has 
been shown to reverse some changes in the echocardiographic 
parameters and exercise tolerance in patients on THST for 
benign disease.76,77 It remains to be seen whether this might 
translate into meaningful benefits to the patients.
There are relatively few studies on TRM-related clinical 
outcomes in these patients. The relevance of the outcomes, 
assessed in the studies included in the present review, to the 
individual patient with DTC remains debatable. In particular, 
there is a paucity of studies examining fracture risk, major 
adverse cardiovascular events, and long-term TRM. Another 
key area requiring further work is the long-term effects of 
hypoparathyroidism, especially in DTC patients. Most of 
the studies reviewed either did not feature hypoparathyroid 
patients or excluded them. Although, in general, the preva-
lence of postthyroidectomy permanent hypoparathyroidism 
is felt to be low, in some studies it is as high as 12% and 
may be higher in procedures carried out for malignancy. 
There is evidence from benign disease that patients with 
hypoparathyroidism have increased BMD related to the 
general population,78 and therefore one might hypothesize 
that hypoparathyroidism in a patient on THST might offer 
some protection against the thyroxine-mediated loss of 
BMD. There is also some evidence that this translates into a 
reduced risk of fracture in these patients.13 However, this is 
controversial, and the patients may be affected by concurrent 
treatments such as calcium and vitamin D supplementation. 
In addition, although there may be a reduction in the loss 
of BMD, other dynamics of bone turnover may be affected, 
resulting in adverse outcomes.79
Strengths
The systematic search strategy has ensured that this review 
is comprehensive, as shown by the large number of papers 
retrieved in the original search. Only papers strictly relevant 
to the review question have been included, and studies of 
short-term outcomes were excluded as were those with 
nonstandard treatment interventions. Studies without clear 
methodology or not reflective of standard practice did not 
influence the evidence synthesis.
Limitations
The studies included had significant heterogeneity in terms of 
treatment regimes, target TSH levels, follow-up, and outcome 
Table 4 Summary of evidence for the effects of long-term TSH 
suppression in DTC patients on cognitive function, quality of life, 
and glucose tolerance
Variable Evidence of reduction Evidence of no effect
Cognitive function 2 of 3 studies62,63 1 of 3 studies16
Quality of life 6 of 7 studies63,64,66–69 1 of 7 studies65
Glucose tolerance 2 of 3 studies58,72 1 of 3 studies70
Abbreviations: DTC, differentiated thyroid cancer; TSH, thyroid-stimulating 
hormone.
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variables, and this precluded the possibility of meaningful 
meta-analysis. The majority of studies, particularly those 
of nonskeletal outcomes, included only small numbers of 
patients. This highlights the need for studies with a larger 
number of patients. It is possible that some relevant studies 
might not have been included, especially those in non-English 
language literature; time and logistic considerations pre-
cluded their inclusion.
Further work
There appears to be sufficient evidence to highlight the 
potential of long-term TRM in patients with DTC to warrant 
further investigation on a larger and more systematic scale. 
A multicenter study of long-term skeletal, cardiovascular, 
and other outcomes including the quality of life in the DTC 
population would help to elucidate the adverse effects of 
treatment. 
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